Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7140170 | 0.93 | GFER (0.54) | GFERMAOBCA2MAOAALDH1A1 | |
| SCHEMBL4281793 | 0.93 | MAOB (0.64) | GFERMAOBCA2MAOAALDH1A1 | |
| SCHEMBL4300050 | 0.91 | MAOB (0.61) | GFERMAOBCA2MAOAALDH1A1 | |
| SCHEMBL2380716 | 0.91 | MAOB (0.61) | GFERMAOBCA2MAOAALDH1A1 | |
| SCHEMBL9806863 | 0.91 | MAOB (0.61) | GFERMAOBCA2MAOAALDH1A1 | |
| SCHEMBL1452380 | 0.91 | MAOB (0.61) | GFERMAOBCA2MAOAALDH1A1 | |
| SCHEMBL10357817 | 0.91 | MAOB (0.61) | GFERMAOBCA2MAOAALDH1A1 | |
| SCHEMBL239040 | 0.87 | CA2 (0.60) | CA2ALDH1A1CYP3A4TDP1CYP4A11 | |
| SCHEMBL1049854 | 0.85 | HTR2A (0.60) | CA2ALDH1A1TDP1CYP4A11LOXL2 | |
| SCHEMBL6051 | 0.84 | GFER (0.68) | GFERMAOBCA2MAOAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117451808-A | Titanium nitride microelectrode array, preparation method and multichannel molecular detection device | 上海新微技术研发中心有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-1799791-B1 | PHOTOCROSSLINKABLE MATERIALS | ROLIC AG (CH) | 2016-01-13 | — | — | EP | claimed |
| US-4904275-A | OXIDIZER | L'OREAL (FR) | 1990-02-27 | — | — | US | claimed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-118871548-A | Photoalignment materials | 罗利克技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| CN-118530557-A | High-heat-conductivity plastic for energy-saving LED light source and preparation method thereof | 江苏德海汽车科技股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024117789-A1 | PLK1 DEGRADATION INDUCING COMPOUNDS WITH INCREASED RIGIDITY | UPPTHERA, INC. (KR) | 2024-06-06 | — | — | WO | disclosed |
| CN-118027412-A | Photo-alignment material | 罗利克技术有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
| EP-0511879-A1 | Pyrazine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
| EP-0257616-B1 | DIHYDROPYRIDINE DERIVATES AND PHARMACEUTICAL COMPOSITION THEREOF | THE GREEN CROSS CORPORATION (JP) | 1992-10-28 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4886819-A | TREATMENT OF HYPERTENSION AND PROPHYLAXIS | THE GREEN CROSS CORPORATION (JP) | 1989-12-12 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| EP-0257616-A2 | Dihydropyridine derivates and pharmaceutical composition thereof | THE GREEN CROSS CORPORATION (JP) | 1988-03-02 | — | — | EP | disclosed |
| US-4332809-A | ANTIALLERGENS | TANABE SEIYAKU CO., LTD. (JP) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | GFER 2160/4885MAOB 629/4885CA2 2235/4885 |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | GFER 3335/4885MAOB 1537/4885CA2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.